17:34 , Aug 3, 2018 |  BC Week In Review  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment and...
18:16 , Jul 30, 2018 |  BC Extra  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment and...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Company News

Daiichi, Glycotope partner for cancer ADC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Glycotope GmbH (Berlin, Germany) partnered to develop an antibody-drug conjugate (ADC) to treat cancer by combining Daiichi's ADC technology with Glycotope's PankoMab-GEX, a humanized IgG1 antibody targeting mucin 1...
17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
16:41 , Jun 22, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Diagnostic assays; cell-free assays; plasma markers A five-protein signature in extracellular vesicles isolated from plasma could help diagnose PDAC. The assay involves two steps: addition of patient plasma samples to a gold plasmonic chip-based microarray...
20:10 , Mar 24, 2017 |  BC Week In Review  |  Company News

Bavarian Nordic, Roche deal

Bavarian Nordic will conduct a Phase II bladder cancer trial combining its CV301 with Roche’s Tecentriq atezolizumab. Both companies will share data from the trial, which is slated to begin around YE17. The Phase II trial...
19:51 , Mar 15, 2017 |  BC Week In Review  |  Clinical News

TG4010: Ph II started

Transgene said investigators began an open-label, U.S. Phase II trial to evaluate subcutaneous TG4010 plus IV Opdivo nivolumab in 14-day courses in about 33 patients who have failed 1 prior platinum-based therapy. Patients will receive...
21:59 , Jan 5, 2017 |  BC Week In Review  |  Clinical News

CV-301: Ph I/II started

Bavarian Nordic began an open-label, U.S. Phase I/II trial of CV-301 in about 120 patients who have failed prior therapy. The dose-escalation Phase I portion will evaluate CV-301 alone in 40 patients and the Phase...